May/June 2014

Gazyva is a novel anti-CD20 monoclonal antibody approved, in combination with chlorambucil, for the treatment of previously untreated chronic lymphocytic leukemia patients.

Clinical trial results show that several new combination therapies offer great promise for the treatment of challenging neuroendocrine tumors in the gastrointestinal area.

Preparation for URAC accreditation requires a careful review of a specialty pharmacy's customer service, specialty drug management, operations, and patient management procedures.

Pharmaceutical manufacturers are increasingly looking to independent specialty pharmacies to play a key role in the launch of new products, harnessing the power of the independents' ability to devote time and resources to patient care.

With cancer ranking third among disease states in specialty spending, there is a growing emphasis on programs that focus on cost management and patient adherence to complex medication regimens.

Assessment, interventions, and outcomes information is vital to specialty pharmacy stakeholders.

The complexities of cancer and the ever-changing medication regimens employed in its treatment call for the specialized competencies of oncology-focused pharmacies. High-touch care and oncology expertise can improve outcomes.

Oncology nurses help improve patient outcomes through their dedication and expertise.

Selection of the right distribution model is of key importance in the launch of a specialty product, where each of the stakeholders has specific needs and requirements that must be met.